Why the study?
Does the application of NICE guidance for recent-onset chest pain safely exclude patients from further investigation without missing significant CAD or MACE?
Does the application of NICE guidance for recent-onset chest pain safely exclude patients from further investigation without missing significant CAD or MACE?
Strict adherence to NICE chest pain guidance may inappropriately exclude a significant proportion of patients who are subsequently diagnosed with significant CAD or experience MACE.
Answers are grounded in this paper and cite their sources.
NICE-negative patients harbor appreciable CAD despite similar MACE; leaves open whether guidance safely excludes investigation without prospective validation.
OBJECTIVE: To describe the clinical outcomes of patients for whom National Institute for Health and Care Excellence (NICE) recent-onset chest pain guidance would not have recommended further investigation, compared with those of patients where further investigation would have been recommended. METHODS: 557 consecutive patients with recent-onset chest pain attending rapid-access chest pain clinics (RACPC) in two district general hospitals over a 9-month period were retrospectively reviewed. Likelihood of coronary artery disease (CAD) was calculated according to NICE-defined modified Diamond-Forrester criteria. Patients were categorised into those for whom NICE guidelines recommend (NICE-Y) and do not recommend (NICE-N) further investigation. Main outcome measures were subsequent diagnosis of significant CAD and major adverse cardiac events (MACE) at 6 months. RESULTS: 187/557 (33.6%) patients comprised NICE-Y group, with 370/557 (66.4%) in NICE-N group. 360/370 (97.3%) of NICE-N group would have been excluded from further investigation due to non-anginal chest pain. Of 92/557 (16.5%) patients subsequently diagnosed with significant CAD, 35/557 (9.5%) were from NICE-N group versus 57/557 (30.5%, p<0.0001) from NICE-Y group. Of 11 patients experiencing at least one MACE, 7/557 (1.9%) were from NICE-N group, versus 4/557 (2.1%, p=1.000) from NICE-Y group. CONCLUSIONS: The rigid application of NICE chest pain guidance to a RACPC population may result in up to two-thirds of patients being excluded from further cardiac investigation. Potentially, up to 10% of these patients may subsequently be diagnosed with significant CAD, with up to 2% potentially experiencing a major adverse cardiac event.
No takes yet. Share an insight, caveat, or question.
Patterson et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: